Create Account | Sign In: Author or Forum

Search Symptoms

Category: Family Medicine | Gastroenterology | Infections | Internal Medicine | Oncology | Pathology | Pharmacy | Journal

Back to Journal Articles

For Hepatitis B Patients, Aspirin Tied to Lower Risk of HCC

Last Updated: October 20, 2017.

Aspirin therapy is associated with a reduced risk of hepatitis B virus-related hepatocellular carcinoma, according to a study scheduled for presentation at The Liver Meeting, held by the American Association for the Study of Liver Diseases from Oct. 20 to 24 in Washington, D.C.

FRIDAY, Oct. 20, 2017 (HealthDay News) -- Aspirin therapy is associated with a reduced risk of hepatitis B virus-related hepatocellular carcinoma (HCC), according to a study scheduled for presentation at The Liver Meeting, held by the American Association for the Study of Liver Diseases from Oct. 20 to 24 in Washington, D.C.

Teng-Yu Lee, M.D., Ph.D., from Taichung Veterans General Hospital in Taiwan, and colleagues used data from Taiwan's National Health Insurance Research Database from 1998 to 2012. Patients with non-hepatitis B infections were excluded, as were those with HCC before the follow-up index dates. A total of 1,553 patients who continuously received daily aspirin ≥90 days were randomly matched (1-to-4 ratio) with 6,212 patients who never received anti-platelet therapy based on baseline characteristics, the index date, and nucelos(t)ide analogue (NA) use during follow-up.

The researchers found that the cumulative incidence of HCC in the treated group was significantly lower than that in the untreated group in five years (2.86 percent versus 5.59 percent). Aspirin therapy was independently associated with a reduced HCC risk (hazard ratio [HR], 0.63) in a multivariable regression analysis. An increased HCC risk was independently associated with older age (HR, 1.03 per year), male gender (HR, 2.65), cirrhosis (HR, 1.89), and diabetes mellitus (HR, 1.51). NA (HR, 0.57) and statin (HR, 0.57) use were associated with a decreased HCC risk.

"For effectively preventing HBV‐related liver cancer, the findings of this study may help hepatologists treat patients with chronic HBV infection in the future, particularly for those who are not indicated for antiviral therapy. We are pursuing prospective investigations for further confirming the findings," Lee said in a statement.

One author disclosed financial ties to the pharmaceutical industry.

Abstract 223
More Information


Previous: High Percentage of HIV-Diagnosed Women Not in Care Next: Clinician Job Satisfaction Linked to Improved Burnout Scores

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: